NASDAQ:FCSC - Fibrocell Stock Price, Price Target & More

Get Started

$0.8301 +0.03 (+3.75 %)

(As of 05/21/2018 12:19 PM ET)

Previous Close$0.80

Today's Range$0.8051 - $0.92

52-Week Range$0.51 - $4.64

Volume2.80 million shs

Average Volume621,269 shs

Market Capitalization$22.68 million

P/E Ratio-0.50

Dividend YieldN/A

Beta0.45

About Fibrocell (NASDAQ:FCSC)

Fibrocell Science, Inc., an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin and connective tissues in the United States. The company's gene therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, a gene therapy for localized scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions. It has collaboration agreement with Intrexon Corporation for the development of FCX-007, FCX-013, and products for the treatment of chronic inflammation and degenerative diseases of human joints. The company was formerly known as Isolagen, Inc. and changed its name to Fibrocell Science, Inc. in September 2009. Fibrocell Science, Inc. was incorporated in 1992 and is based in Exton, Pennsylvania.

Receive FCSC News and Ratings via Email

Sign-up to receive the latest news and ratings for FCSC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

SymbolNASDAQ:FCSC

CUSIPN/A

Webwww.fibrocell.com

Phone484-713-6000

Debt

Debt-to-Equity RatioN/A

Current Ratio6.75

Quick Ratio6.75

Price-To-Earnings

Trailing P/E Ratio-0.50

Forward P/E Ratio-1.73

P/E GrowthN/A

Sales & Book Value

Annual Sales$350,000.00

Price / Sales67.26

Cash FlowN/A

Price / CashN/A

Book Value$0.35 per share

Price / Book2.37

Profitability

EPS (Most Recent Fiscal Year)($1.65)

Net Income$-16,240,000.00

Net MarginsN/A

Return on Equity-886.87%

Return on Assets-115.44%

Miscellaneous

Employees20

Outstanding Shares28,360,000

Fibrocell (NASDAQ:FCSC) Frequently Asked Questions

What is Fibrocell's stock symbol?

Fibrocell trades on the NASDAQ under the ticker symbol "FCSC."

How were Fibrocell's earnings last quarter?

Fibrocell (NASDAQ:FCSC) released its quarterly earnings data on Thursday, May, 10th. The company reported ($0.11) earnings per share for the quarter, beating analysts' consensus estimates of ($0.17) by $0.06. View Fibrocell's Earnings History.

When is Fibrocell's next earnings date?

Fibrocell is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Fibrocell.

What price target have analysts set for FCSC?

3 analysts have issued 12-month price objectives for Fibrocell's shares. Their forecasts range from $6.00 to $7.00. On average, they expect Fibrocell's stock price to reach $6.50 in the next twelve months. View Analyst Ratings for Fibrocell.

Who are some of Fibrocell's key competitors?

Some companies that are related to Fibrocell include Gemphire Therapeutics (GEMP), Axsome Therapeutics (AXSM), Xenon Pharmaceuticals (XENE), Vivus (VVUS), Novelion Therapeutics (NVLN), Trillium Therapeutics (TRIL), Eyenovia (EYEN), OncoSec Medical (ONCS), Cardiome Pharma (CRME), Novan (NOVN), Pharmaxis (PXSLY), Aileron Therapeutics (ALRN), Medicure Inc. Common Stock (MCUJF), Scynexis (SCYX) and GT Biopharma (GTBP).

Who are Fibrocell's key executives?

Fibrocell's management team includes the folowing people:

Mr. John Michael Maslowski, Pres, CEO, PFO, Principal Accounting Officer & Director (Age 43)
Mr. Robert G. Partridge, VP of Global Marketing, Communications and Investor Relations
Ms. Elizabeth A. Browning, Exec. VP of Marketing
Ms. Michele Mchugh-Mazzatta, VP of Sales
Dr. Pierre Compte, Managing Director of Switzerland

Has Fibrocell been receiving favorable news coverage?

News stories about FCSC stock have been trending very positive recently, Accern Sentiment reports. Accern scores the sentiment of news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Fibrocell earned a daily sentiment score of 0.51 on Accern's scale. They also assigned news articles about the company an impact score of 47.26 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

Who are Fibrocell's major shareholders?

Fibrocell's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Point72 Asset Management L.P. (1.41%). Company insiders that own Fibrocell stock include David Pernock and Randal J Kirk. View Institutional Ownership Trends for Fibrocell.

Which institutional investors are buying Fibrocell stock?

FCSC stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P.. Company insiders that have bought Fibrocell stock in the last two years include David Pernock and Randal J Kirk. View Insider Buying and Selling for Fibrocell.

How do I buy shares of Fibrocell?

Shares of FCSC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Fibrocell's stock price today?

One share of FCSC stock can currently be purchased for approximately $0.8301.

How big of a company is Fibrocell?

Fibrocell has a market capitalization of $22.68 million and generates $350,000.00 in revenue each year. The company earns $-16,240,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis. Fibrocell employs 20 workers across the globe.

How can I contact Fibrocell?

Fibrocell's mailing address is 405 EAGLEVIEW BOULEVARD, EXTON PA, 19341. The company can be reached via phone at 484-713-6000 or via email at [email protected]

MarketBeat Community Rating for Fibrocell (FCSC)

Community Ranking:		2.7 out of 5 ( )
Outperform Votes:		165 (Vote Outperform)
Underperform Votes:		138 (Vote Underperform)
Total Votes:		303

MarketBeat's community ratings are surveys of what our community members think about Fibrocell and other stocks. Vote "Outperform" if you believe FCSC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FCSC will underperform the S&P 500 over the long term. You may vote once every thirty days.

Fibrocell (NASDAQ:FCSC) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

3 Wall Street analysts have issued ratings and price targets for Fibrocell in the last 12 months. Their average twelve-month price target is $6.50, suggesting that the stock has a possible upside of 683.04%. The high price target for FCSC is $7.00 and the low price target for FCSC is $6.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	3.00	3.00	3.00	3.00
Ratings Breakdown:	0 Sell Rating(s) 0 Hold Rating(s) 3 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 3 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 3 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 3 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$6.50	$6.50	$5.00	$5.5333
Price Target Upside:	683.04% upside	1,020.69% upside	646.27% upside	83.22% upside

Fibrocell (NASDAQ:FCSC) Consensus Price Target History

Price Target History for Fibrocell (NASDAQ:FCSC)

Fibrocell (NASDAQ:FCSC) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
5/10/2018	HC Wainwright	Set Price Target	Buy	$6.00	High
4/2/2018	Griffin Securities	Reiterated Rating	Buy		Low
9/11/2017	Canaccord Genuity	Reiterated Rating	Buy	$3.00 ➝ $7.00	Low
3/7/2017	Rodman & Renshaw	Initiated Coverage	Buy ➝ Buy	$2.00	N/A
6/8/2016	Roth Capital	Reiterated Rating	Buy	$5.00	N/A
6/8/2016	Wedbush	Reiterated Rating	Neutral	$1.50 ➝ $4.00	N/A

(Data available from 5/21/2016 forward)

Fibrocell (NASDAQ:FCSC) Earnings History and Estimates Chart

Earnings by Quarter for Fibrocell (NASDAQ:FCSC)

Fibrocell (NASDAQ:FCSC) Earnings Estimates

2018 EPS Consensus Estimate: ($1.01)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	1	($0.26)	($0.26)	($0.26)
Q2 2018	1	($0.29)	($0.29)	($0.29)
Q3 2018	1	($0.23)	($0.23)	($0.23)
Q4 2018	1	($0.23)	($0.23)	($0.23)

Fibrocell (NASDAQ FCSC) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
8/7/2018		($0.14)					N/A
5/10/2018	Q1 2018	($0.17)	($0.11)			View	N/A
3/19/2018	Q4 2017	($0.23)	($0.65)			View	Listen
11/13/2017	Q3 2017	($0.41)	($0.34)			View	N/A
8/9/2017	Q2 2017	($0.31)	($0.31)			View	Listen
5/10/2017	Q1 2017	($0.29)	($0.58)			View	N/A
3/9/2017	Q4 2016	($0.81)	($0.33)	$0.02 million	$0.04 million	View	N/A
11/3/2016	Q316	($0.15)	($0.05)	$0.07 million	$0.22 million	View	N/A
8/4/2016	Q2 2016	($0.39)	($0.42)	$0.04 million	$0.09 million	View	N/A
5/5/2016	Q1 2016	($0.48)	$0.12	$0.07 million	$0.02 million	View	N/A
3/10/2016	Q415	($0.17)	($0.40)	$0.07 million	$0.08 million	View	Listen
11/5/2015	Q315	($0.16)	($0.07)	$0.06 million	$0.08 million	View	N/A
8/6/2015	Q215	($0.16)	($0.17)	$0.09 million	$0.14 million	View	N/A
5/8/2015	Q1 2015	($0.16)	($0.17)	$0.05 million	$0.19 million	View	N/A
3/13/2015	Q4 2014	($0.16)	($0.16)	$0.06 million	$0.06 million	View	N/A
11/7/2014	Q3 14	($0.14)	($0.17)	$0.06 million	$0.02 million	View	N/A
8/11/2014	Q2 2014	($0.18)	($0.08)	$0.07 million	$0.06 million	View	N/A
5/19/2014	Q114	($0.15)	($0.35)	$0.05 million	$0.05 million	View	N/A
3/17/2014	Q414	($0.26)	($0.14)	$0.05 million	$0.04 million	View	N/A
11/14/2013	Q3 2013	($0.63)	($1.44)	$0.07 million	$0.07 million	View	N/A
5/15/2013	Q1 2013		($0.66)		$0.03 million	View	N/A
11/17/2011	Q3 2011	($4.50)	($1.35)			View	N/A
8/15/2011	Q2 2011		($23.85)			View	N/A
5/18/2011	Q1 2011	($9.75)	($14.33)			View	N/A
11/18/2010	Q3 2010		($6.98)			View	N/A

(Earnings results data provided by Zacks Investment Research)

Fibrocell (NASDAQ:FCSC) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Fibrocell (NASDAQ FCSC) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.20%
Institutional Ownership Percentage: 37.32%

Insider Trading History for Fibrocell (NASDAQ:FCSC)

Institutional Ownership by Quarter for Fibrocell (NASDAQ:FCSC)

Fibrocell (NASDAQ FCSC) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/11/2017	Randal J Kirk	Major Shareholder	Buy	2,727,273	$0.77	$2,100,000.21
12/2/2016	David Pernock	Chairman	Buy	50,000	$0.92	$46,000.00	105,600
11/13/2015	David Pernock	CEO	Buy	3,000	$5.00	$15,000.00	55,600
8/11/2015	David Pernock	CEO	Buy	3,500	$6.54	$22,890.00
7/27/2015	Randal J Kirk	Major Shareholder	Buy	975,987	$5.80	$5,660,724.60
5/13/2015	David Pernock	CEO	Buy	16,600	$4.30	$71,380.00
12/12/2014	David Pernock	CEO	Buy	5,000	$2.52	$12,600.00
11/20/2014	David Pernock	CEO	Buy	5,000	$2.54	$12,700.00
11/20/2014	John Michael Maslowski	VP	Buy	1,000	$2.54	$2,540.00
6/5/2014	Christine St.Clare	Director	Buy	10,000	$3.00	$30,000.00
6/5/2014	David Pernock	CEO	Buy	12,500	$2.95	$36,875.00
6/4/2014	Kelvin Moore	Director	Buy	4,557	$2.99	$13,625.43
6/4/2014	Randal J Kirk	Major Shareholder	Buy	400,000	$2.90	$1,160,000.00
1/24/2014	Randal J Kirk	Major Shareholder	Buy	1,024,590	$4.88	$4,999,999.20
11/21/2013	David Pernock	CEO	Buy	10,000	$3.69	$36,900.00
11/20/2013	Gregory L Weaver	CFO	Buy	10,000	$3.51	$35,100.00
10/1/2013	Randal J Kirk	Major Shareholder	Buy	3,658,536	$4.10	$14,999,997.60
7/26/2013	Randal J Kirk	Major Shareholder	Buy	1,243,781	$6.03	$7,499,999.43

(Data available from 1/1/2013 forward)

Fibrocell (NASDAQ FCSC) News Headlines

Source:

Date	Headline
	Fibrocell's gene therapy FCX-007 shows positive effect in RDEB study; shares up 4% seekingalpha.com - May 21 at 12:33 PM
	Fibrocell Science (FCSC) Announces Interim Results and Progress of Phase 1/2 Clinical Trial of FCX-007 Gene Therapy www.streetinsider.com - May 21 at 8:15 AM
	Form 8-K Fibrocell Science, Inc. For: May 21 www.streetinsider.com - May 21 at 8:15 AM
	Fibrocell Reports on Interim Results and Progress of Phase 1/2 Clinical Trial of FCX-007 Gene Therapy for Recessive ... www.globenewswire.com - May 21 at 8:15 AM
	BRIEF-Fibrocell Reports On Interim Results And Progress Of Phase 1/2 Clinical Trial Of FCX-007 Gene Therapy For ... www.reuters.com - May 21 at 8:15 AM
	Fibrocell Reports on Interim Results and Progress of Phase 1/2 Clinical Trial of FCX-007 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa finance.yahoo.com - May 21 at 8:15 AM
	Brokerages Anticipate Fibrocell (FCSC) Will Announce Earnings of -$0.11 Per Share www.americanbankingnews.com - May 20 at 9:28 PM
	Fibrocell Announces Oral Presentation at 7th International Investigative Dermatology Meeting finance.yahoo.com - May 16 at 5:42 PM
	Fibrocell (FCSC) Lifted to Buy at Zacks Investment Research www.americanbankingnews.com - May 15 at 10:58 PM
	Form 10-Q Fibrocell Science, Inc. For: Mar 31 www.streetinsider.com - May 11 at 8:27 AM
	Fibrocell (FCSC) Announces Quarterly Earnings Results, Beats Estimates By $0.06 EPS www.americanbankingnews.com - May 10 at 4:17 PM
	Fibrocell (FCSC) Given a $6.00 Price Target by HC Wainwright Analysts www.americanbankingnews.com - May 10 at 1:28 PM
	Fibrocell Reports First Quarter 2018 Financial Results and Recent Highlights finance.yahoo.com - May 10 at 8:24 AM
	Fibrocell (FCSC) Upgraded to "Sell" by ValuEngine www.americanbankingnews.com - May 4 at 12:13 AM
	Brokerages Expect Fibrocell (FCSC) to Announce -$0.17 EPS www.americanbankingnews.com - May 3 at 6:52 PM
	Fibrocell to Host Conference Call and Webcast on Thursday, May 10, 2018 to Discuss First Quarter 2018 Financial Results and Recent Highlights finance.yahoo.com - May 3 at 8:17 AM
	Fibrocell (FCSC) Scheduled to Post Quarterly Earnings on Tuesday www.americanbankingnews.com - May 1 at 7:46 AM
	Fibrocell (FCSC) Rating Increased to Buy at Zacks Investment Research www.americanbankingnews.com - April 19 at 12:28 AM
	Form 8-K Fibrocell Science, Inc. For: Apr 18 www.streetinsider.com - April 18 at 5:45 PM
	Health Care Sector Update for 04/18/2018: SLDB,FCSC,ABT,ENDP,EGRX www.nasdaq.com - April 18 at 5:45 PM
	BRIEF-Fibrocell Announces Review Of Strategic Alternatives www.reuters.com - April 18 at 5:45 PM
	Fibrocell Announces Review of Strategic Alternatives globenewswire.com - April 18 at 8:16 AM
	Fibrocell Science shares halted pending news seekingalpha.com - April 18 at 8:10 AM
	Fibrocell (FCSC) Expected to Announce Earnings of -$0.17 Per Share www.americanbankingnews.com - April 16 at 9:21 AM
	Fibrocell Science (FCSC) Lowered to "Sell" at ValuEngine www.americanbankingnews.com - April 14 at 8:37 PM
	Fibrocell Science (FCSC) Given a $6.00 Price Target at HC Wainwright www.americanbankingnews.com - April 11 at 7:53 PM
	Fibrocell Science (FCSC) Rating Lowered to Sell at Zacks Investment Research www.americanbankingnews.com - April 10 at 5:02 PM
	Fibrocell to Present at 6th Annual Cell & Gene Therapy Investor Day and 2018 World Orphan Drug Congress USA finance.yahoo.com - April 10 at 8:27 AM
	Fibrocell Science (FCSC) Cut to Strong Sell at ValuEngine www.americanbankingnews.com - April 9 at 11:35 AM
	Fibrocell Science (FCSC) Receives "Buy" Rating from Griffin Securities www.americanbankingnews.com - April 6 at 9:10 AM
	Zacks: Analysts Anticipate Fibrocell Science Inc (FCSC) Will Post Earnings of -$0.22 Per Share www.americanbankingnews.com - March 30 at 1:20 PM
	Reviewing OptiNose (OPTN) & Fibrocell Science (FCSC) www.americanbankingnews.com - March 30 at 9:38 AM
	Fibrocell Science (FCSC) PT Set at $6.00 by HC Wainwright www.americanbankingnews.com - March 28 at 2:06 PM
	Zacks Investment Research Lowers Fibrocell Science (FCSC) to Hold www.americanbankingnews.com - March 24 at 12:28 AM
	Fibrocell Science's (FCSC) CEO John Maslowski on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha seekingalpha.com - March 20 at 8:28 AM
	Fibrocell Science (FCSC) Releases Earnings Results, Beats Estimates By $0.38 EPS www.americanbankingnews.com - March 19 at 1:48 PM
	HC Wainwright Analysts Give Fibrocell Science (FCSC) a $6.00 Price Target www.americanbankingnews.com - March 19 at 1:03 PM
	Earnings Scheduled For March 19, 2018 - Benzinga www.benzinga.com - March 19 at 8:22 AM
	Does Fibrocell Science Inc’s (NASDAQ:FCSC) Past Performance Indicate A Stronger Future? finance.yahoo.com - March 19 at 8:22 AM
	Fibrocell Reports 2017 Financial Results and Recent Highlights finance.yahoo.com - March 19 at 8:22 AM
	Pre-Market Earnings Report for March 19, 2018 : CSIQ, MDWD, LEJU, FCSC - Nasdaq www.nasdaq.com - March 17 at 8:26 AM
	Fibrocell Science Inc (FCSC) Sees Large Decrease in Short Interest www.americanbankingnews.com - March 14 at 1:38 AM
	Fibrocell Science (FCSC) Rating Increased to Buy at Zacks Investment Research www.americanbankingnews.com - March 13 at 10:52 PM
	Zacks: Brokerages Expect Fibrocell Science Inc (FCSC) Will Post Earnings of -$0.23 Per Share www.americanbankingnews.com - March 13 at 12:03 PM
	Fibrocell Science (FCSC) Set to Announce Quarterly Earnings on Monday www.americanbankingnews.com - March 13 at 10:56 AM
	Fibrocell to Host Conference Call and Webcast on Monday, March 19, 2018 to Discuss 2017 Financial Results and ... - GlobeNewswire (press release) globenewswire.com - March 13 at 8:25 AM
	Fibrocell to Host Conference Call and Webcast on Monday, March 19, 2018 to Discuss 2017 Financial Results and ... - Nasdaq www.nasdaq.com - March 12 at 9:02 AM
	Fibrocell to Host Conference Call and Webcast on Monday, March 19, 2018 to Discuss 2017 Financial Results and Recent Highlights finance.yahoo.com - March 12 at 9:02 AM
	Fibrocell Science (FCSC) Stock Rating Lowered by Zacks Investment Research www.americanbankingnews.com - March 7 at 11:22 PM
	Fibrocell Science (FCSC) Upgraded to Buy at Zacks Investment Research www.americanbankingnews.com - March 6 at 10:52 PM

Fibrocell (NASDAQ:FCSC) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Fibrocell (NASDAQ:FCSC) Income Statement, Balance Sheet and Cash Flow Statement

Fibrocell (NASDAQ FCSC) Stock Chart for Monday, May, 21, 2018

Loading chart…

This page was last updated on 5/21/2018 by MarketBeat.com Staff